ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalo… Read more
Market Cap & Net Worth: ExpreS2ion Biotech Holding AB (EXPRS2)
ExpreS2ion Biotech Holding AB (ST:EXPRS2) has a market capitalization of $1.60 Million (Skr17.93 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #35668 globally and #567 in its home market, demonstrating a -0.78% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ExpreS2ion Biotech Holding AB's stock price Skr5.08 by its total outstanding shares 3530233 (3.53 Million).
ExpreS2ion Biotech Holding AB Market Cap History: 2016 to 2026
ExpreS2ion Biotech Holding AB's market capitalization history from 2016 to 2026. Data shows change from $63.16 Million to $1.60 Million (-29.68% CAGR).
Index Memberships
ExpreS2ion Biotech Holding AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$4.63 Billion | 0.03% | #195 of 281 |
Weight: ExpreS2ion Biotech Holding AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ExpreS2ion Biotech Holding AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ExpreS2ion Biotech Holding AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.37x
ExpreS2ion Biotech Holding AB's market cap is 1.37 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $63.16 Million | $4.65 Million | -$8.54 Million | 13.58x | N/A |
| 2017 | $90.94 Million | $9.79 Million | -$9.84 Million | 9.28x | N/A |
| 2018 | $55.77 Million | $8.87 Million | -$16.82 Million | 6.29x | N/A |
| 2019 | $34.03 Million | $13.83 Million | -$16.70 Million | 2.46x | N/A |
| 2020 | $103.29 Million | $5.26 Million | -$31.71 Million | 19.64x | N/A |
| 2021 | $348.34 Million | $12.23 Million | -$43.92 Million | 28.47x | N/A |
| 2022 | $165.36 Million | $5.09 Million | -$118.61 Million | 32.51x | N/A |
| 2023 | $22.70 Million | $7.05 Million | -$91.40 Million | 3.22x | N/A |
| 2024 | $6.48 Million | $3.01 Million | -$36.04 Million | 2.15x | N/A |
| 2025 | $5.00 Million | $3.66 Million | -$38.09 Million | 1.37x | N/A |
Competitor Companies of EXPRS2 by Market Capitalization
Companies near ExpreS2ion Biotech Holding AB in the global market cap rankings as of March 19, 2026.
Key companies related to ExpreS2ion Biotech Holding AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ExpreS2ion Biotech Holding AB Historical Marketcap From 2016 to 2026
Between 2016 and today, ExpreS2ion Biotech Holding AB's market cap moved from $63.16 Million to $ 1.60 Million, with a yearly change of -29.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr1.60 Million | -68.05% |
| 2025 | Skr5.00 Million | -22.82% |
| 2024 | Skr6.48 Million | -71.44% |
| 2023 | Skr22.70 Million | -86.27% |
| 2022 | Skr165.36 Million | -52.53% |
| 2021 | Skr348.34 Million | +237.25% |
| 2020 | Skr103.29 Million | +203.57% |
| 2019 | Skr34.03 Million | -38.99% |
| 2018 | Skr55.77 Million | -38.67% |
| 2017 | Skr90.94 Million | +43.98% |
| 2016 | Skr63.16 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ExpreS2ion Biotech Holding AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.60 Million USD |
| MoneyControl | $1.60 Million USD |
| MarketWatch | $1.60 Million USD |
| marketcap.company | $1.60 Million USD |
| Reuters | $1.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.